Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2022-09-30 Regulatory Filings
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings
2022-09-30 English
FORM 6-K
Regulatory Filings
2022-09-26 English
Comunicado del Consejo de Adminsitración de Grifols
Regulatory Filings Classification · 95% confidence The document is a formal communication from Grifols, S.A., dated September 25, 2022, issued under Spanish securities law ('OTRA INFORMACIÓN RELEVANTE'). It provides a high-level update on strategic execution, innovation projects (Biotest AG), plasma collection volumes, operational efficiencies, management changes, and debt reduction efforts. Crucially, it mentions that Grifols intends to publish quarterly earnings reports starting Q1 2023, but this document itself is not a full financial report (like 10-K or IR). It contains forward-looking statements and operational highlights, which aligns best with a general corporate update or announcement. Since it is not a specific earnings release (ER) which usually contains the actual figures, nor a formal report (10-K, IR), and it is a significant, non-routine disclosure of material information, it fits the criteria for a general Regulatory Filing (RNS) or potentially a Management Report (MDA) if it were more focused on financial explanation. Given the broad nature of the updates (strategy, operations, management, debt outlook) and the context of Spanish regulatory disclosure ('información relevante'), RNS is the most appropriate general category for material, non-standard announcements that don't fit the specific financial report codes. It is not a proxy statement (DEF 14A), a dividend notice (DIV), or a director's dealing report (DIRS).
2022-09-26 Spanish
Regulatory Filings 2022
Regulatory Filings
2022-09-21 English
FORM 6-K
Regulatory Filings
2022-09-07 English
Grifols ha formalizado un acuerdo de colaboración a largo plazo de 15 años de duración renovable con Canadian Blood Services.
Regulatory Filings Classification · 95% confidence The document is a formal communication from Grifols, S.A., referencing Spanish securities law ('artículo 227 del Texto Refundido de la Ley del Mercado de Valores') to communicate 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). The content details a long-term collaboration agreement with Canadian Blood Services regarding the supply of Immunoglobulin (Ig) derived from plasma, including commitments on facility development and supply volumes. This type of material disclosure, which is not a standard periodic report (10-K, IR) or a specific event filing (DIV, DIRS), falls best under general regulatory announcements or significant corporate news that must be disclosed to the market. Given the options, 'Regulatory Filings' (RNS) serves as the appropriate fallback for significant, non-standard corporate disclosures required by market regulations, especially when the text itself is a direct communication of material non-public information rather than an announcement *about* another report (RPA). The document length (2544 chars) is substantial enough to be the primary disclosure, not just a brief announcement of an attachment.
2022-09-07 Spanish

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.